Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls (rSIG)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94304
- Department of Psychiatry and Behavioral Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ages 18-65
- either gender and all ethno-racial categories
- capacity to provide informed consent
- Female participants are expected to use an effective method of birth control throughout the study
Exclusion Criteria:
- Any current or lifetime psychiatric diagnosis
- Current or past use of psychotropic medication
- Pregnant or nursing females
- Major medical or neurological problem
- Presence of metal in the body that is contraindicated for MRI scans
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: [18F]-FTC-146
|
Two 5 mCi [18F]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reliability under test retest conditions
Time Frame: 1 week
|
Regional brain uptake of [18F]FTC-146 will be analyzed by kinetic modeling with metabolite-corrected arterial input functions to establish stability and reproducibility of [18F] FTC-146 VT in humans (n=6) under test and retest conditions.
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Carolyn Rodriguez, MD, PhD, Stanford University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 45678
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Controls
-
NCT07531316Not yet recruitingHealthy Controls
-
NCT01576276Completed
-
NCT00838851TerminatedHealthy Controls
-
NCT03741478Active, not recruiting
-
NCT01460394Completed
-
NCT02097589Completed
Clinical Trials on [18F]-FTC-146
-
NCT06599151Not yet recruitingNeuropathic Pain | Nociceptive Pain | Nerve Pain | MIxed Pain (Nociceptive and Neuropathic)
-
NCT03556137RecruitingRadiculopathy | Neuropathic Pain | Myelopathy | Nociceptive Pain | Spinal Pain | Neurogenic Claudication | Mixed Pain (Nociceptive and Neuropathic)
-
NCT04435821CompletedChronic Pain | Neuropathic Pain | Pediatric Disorder | Nociceptive Pain
-
NCT02753101CompletedSciatica | Complex Regional Pain Syndrome
-
NCT03446248Terminated
-
NCT03173547CompletedIchthyosis Vulgaris
-
NCT06435026CompletedPregnancy | HIV | Prevention
-
NCT03464266CompletedHypoestrogenism | Bone Demineralization | Subclinical Kidney Injury | Bone Microarchitecture